Know Cancer

forgot password

Molecular Screening Analysis Used as Decision Tool for Targeted Molecular Treatment

6 Months
Open (Enrolling)
Metastatic Solid Tumors (Any Localization)

Thank you

Trial Information

Molecular Screening Analysis Used as Decision Tool for Targeted Molecular Treatment

Inclusion Criteria:

- Solid tumors ; Stade IV ; Local relapse or metastatic ; Uncurable

- Age > 6 months

- PS 0/1 or Lansky play scale >= 70%

- Minimum one treatment line, no limit in the prior number of treatment line

- Evaluable or measurable disease

Exclusion Criteria:

- Life expectancy < 3 months

- Symptomatic or progressive radiologic brain metastasis for non-CNS tumors

- Polynuclear neutrophil < 1 x 10^9/L

- Platelets < 100 x 10^9/L

- Hemoglobin < 90 g/L

- ALT/AST > 2.5 N

- bilirubin > 1.5 N

- Creatinine >1.5 N

- Calcemia > ULN

- Phosphate > ULN

- Coagulation anomaly non-indicated for biopsy

Type of Study:


Study Design:

Intervention Model: Single Group Assignment, Masking: Open Label

Outcome Measure:

Progression free survival (PFS) using a targeted treatment selected by molecular profiling compared to the PFS for the most recent regimen

Outcome Description:

Progression according to RECIST criteria or clinical progression or death of any cause

Outcome Time Frame:

From date of start of targeted treatment oriented by MOSCATO until the date of first progression or date of death from any cause, whichever came first, assessed up to 1 year

Safety Issue:


Principal Investigator

Jean-Charles SORIA, MD, PhD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Gustave Roussy, Cancer Campus, Grand Paris


France: Agence Nationale de Sécurité du Médicament et des produits de santé

Study ID:




Start Date:

October 2011

Completion Date:

October 2015

Related Keywords:

  • Metastatic Solid Tumors (Any Localization)